Cannabinoids Company InMed Pharma Posts Smaller Net Loss For FY21
InMed Pharmaceuticals Inc (NASDAQ:INM) reported an FY21 EPS loss of $(1.52) narrower than $(1.71) posted a year ago. On June 30,…
The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 22)
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
The Week In Cannabis: FDA, CDC, Delta-8 THC, WADA, Canopy, Sundial, Canada, LatAm And More
Below is a recap of the main news related to the cannabis industry and markets for the week of September 13, 2021.
Contents
Video: All You Need To Know About Leafly And Its IPO, COO Sam Martin Shares Details On The Co., Upcoming Stock Listing
Benzinga’s Cannabis Insider is a live show for cannabis investors.
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 14)
InMed Pharmaceuticals To Acquire BayMedica, Rare Cannabinoid Manufacturer, For ~$3.66M
InMed Pharmaceuticals (NASDAQ: INM) announced on Monday that it has entered into a definitive agreement to acquire BayMedica Inc., a private company that manufactures rare cannabinoids.
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
Establishes leadership position in manufacturing and commercialization of rare cannabinoids
Positions InMed within large and growing consumer health and wellness cannabinoid markets
Transitions InMed into revenue generating company; acquires pipeline with numerous planned product launches